Select Language
DLL3
DLL3 Overview
| English Name | Delta-like protein 3 | Approved Drugs | 1 |
| Drugs in Clinical Trials | 30 | Target Synonym | Delta-Like Protein 3，Delta3，Delta-Like 3，Drosophila Delta Homolog 3，SCDO1，Delta-Like 3 (Drosophila)，DLL3，Delta (Drosophila)-Like 3，Delta Like Canonical Notch Ligand 3 |
| Highest Development Stage | Approved | ||
| English Name | Delta-like protein 3 |
| Target Synonym | Delta-Like Protein 3，Delta3，Delta-Like 3，Drosophila Delta Homolog 3，SCDO1，Delta-Like 3 (Drosophila)，DLL3，Delta (Drosophila)-Like 3，Delta Like Canonical Notch Ligand 3 |
| Approved Drugs | 1 |
| Drugs in Clinical Trials | 30 |
| Highest Development Stage | Approved |
DLL3 Product List
- Product Category
Protein (19)Cell (2)Cell Grade Beads (1)Kits (1)
- Product Status
Launched (23)
- Species
Human (16)Cynomolgus (4)Rat (1)Rhesus macaque (1)Mouse (1)
- Tag
His Tag (14)- (5)His Tag & Avi Tag (2)Llama IgG Fc Tag (1)Fc Tag (1)
- Conjugate
Unconjugated (13)FITC Labeled (1)Biotin-labeled (2)PE Labeled (1)- (4)APC Labeled (1)AF647 Labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
HOT DL3-H52H4 |  Human | HEK293 | Human DLL3 Protein, His Tag, low endotoxin (MALS verified) |  |  |  |  Add to Cart |
HOT DL3-M52H9 |  Mouse | HEK293 | Mouse DLL3 Protein, His Tag, low endotoxin (HPLC verified) | | | Add to Cart | |
HOT DL3-C52H3 |  Cynomolgus | HEK293 | Cynomolgus DLL3 Protein, His Tag (MALS verified) |  | | | Add to Cart |
CEA-B049 | Human | - | Human DLL3 ELISA Kit | Add to Cart | |||
CHEK-ATP090 | Human | HEK293 | HEK293/Human DLL3 Stable Cell Line |  | Add to Cart | ||
DL3-H5243 | Human | HEK293 | Human DLL3 Protein, His Tag (HPLC verified) |  | | | Add to Cart |
DL3-H525a | Human | HEK293 | Human DLL3 Protein, Llama IgG2b Fc Tag, low endotoxin |  | | | Add to Cart |
DL3-H525c | Human | HEK293 | Human DLL3 (27-215) Protein, Fc Tag (MALS verified) |  | | | Add to Cart |
DL3-H52Ha | Human | HEK293 | Human DLL3 (353-492) Protein, His Tag |  | | | Add to Cart |
DL3-H52Hy | Human | HEK293 | Human DLL3 (176-492) Protein, His Tag, low endotoxin (MALS & SPR verified) |  | | | Add to Cart |
Total: 23
- 1
- 2
- 3
DLL3 Background
Delta-like protein 3 (DLL3) is a transmembrane protein that belongs to the Delta/Serrate/Lag-2 (DSL) family of Notch ligands.May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm. DLL3 protein is expressed on the surface of tumor cells but not in normal adult tissues.
DLL3 Synonyms
Delta3,delta-like 3 (Drosophila),delta-like protein 3,DLL3,Pudgy,SCDO1,SCDO1delta3
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Zocilurtatug pelitecan | ZL-1310; YL-212 | Phase 3 Clinical | Zai Lab (Shanghai) Co Ltd | Small Cell Lung Carcinoma; Solid tumours | Details |
| Obrixtamig | BI-764532; OBT620 | Phase 3 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Carcinoma, Neuroendocrine; Glioma; Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma | Details |
| Alveltamig | ZG-006; ZG006 | Phase 3 Clinical | Gensun Biopharma Inc, Suzhou Zelgen Biopharmaceuticals Co Ltd | Carcinoma, Neuroendocrine; Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours | Details |
| 89Zr-DFO-SC16.56 | 89Zr-DFO-SC16.56 | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Small Cell Lung Carcinoma | Details |
| Gocatamig | HPN-328; MK-6070; DS-3280 | Phase 2 Clinical | Harpoon Therapeutics | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma | Details |
| EB-DART-NK01 | EB-DART-NK01 | Phase 2 Clinical | Beijing Biotech | Small Cell Lung Carcinoma | Details |
| 4sCAR-DLL3 CAR-T Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Glioblastoma; Melanoma | Details | |
| SHR-7787 | SHR-7787; SHR7787 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Small Cell Lung Carcinoma; Solid tumours | Details |
| SHR-4849 | SHR-4849; SHR4849; IDE849; IDE-849 | Phase 2 Clinical | Jiangsu Hengrui Pharmaceutical Group Co Ltd | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma; Solid tumours | Details |
| DLL3-CAR-NK cells Therapy(Tianjin Medical University Cancer Institute and Hospital) | DLL3-CAR-NK cells | Phase 2 Clinical | Tianjin Medical University Cancer Institute And Hospital | Small Cell Lung Carcinoma | Details |
| Peluntamig | PT-217 | Phase 2 Clinical | Phanes Therapeutics Inc | Carcinoma, Neuroendocrine; Neuroendocrine Carcinoma of Lung; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours | Details |
| ML-261 | ML261; ML-261 | Phase 1 Clinical | Moonlight Bio Inc | Carcinoma, Neuroendocrine; Gastroenteropancreatic neuroendocrine tumor; Prostatic Neoplasms; Small Cell Lung Carcinoma | Details |
| NEUK203-13 | NEUK203-13 | Phase 1 Clinical | Neukio Biotherapeutics (Shanghai) Co Ltd | Neuroendocrine Tumors; Small Cell Lung Carcinoma | Details |
| 111In-ABD147 | Phase 1 Clinical | Abdera Therapeutics Inc | Neuroendocrine Tumors; Prostatic Neoplasms, Castration-Resistant; Solid tumours | Details | |
| 111In-ETN029 | 111In-ETN029 | Phase 1 Clinical | Novartis Pharma Ag | Gastroenteropancreatic neuroendocrine tumor; Neuroendocrine Tumors; Prostatic Neoplasms; Small Cell Lung Carcinoma | Details |
| 225Ac-ETN029 | 225Ac-ETN029; [225Ac]Ac-ETN029 | Phase 1 Clinical | Novartis Pharma Ag | Gastroenteropancreatic neuroendocrine tumor; Neuroendocrine Tumors; Prostatic Neoplasms; Small Cell Lung Carcinoma | Details |
| HLX-3901 | HLX-3901 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Carcinoma, Neuroendocrine; Neoplasm Metastasis; Small Cell Lung Carcinoma; Solid tumours | Details |
| 177Lu-DTPA-SC16.56 | 177Lu-DTPA-SC16.56 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Carcinoma, Neuroendocrine; Lung Neoplasms; Neuroendocrine Carcinoma of Lung; Prostatic Neoplasms | Details |
| SYS-6040 | SYS6040; SYS-6040 | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Solid tumours | Details |
| IBI-3009 | IBI3009; IBI-3009 | Phase 1 Clinical | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma; Solid tumours | Details | |
| BL-M14D1 | BL-M14D1 | Phase 1 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Carcinoma, Neuroendocrine; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Solid tumours | Details |
| BHP-01 | BHP-01; BHP01; α-PD-L1/4-1BB DLL3 CAR-T | Phase 1 Clinical | Chengdu Brilliant Pharmaceutical Co Ltd | Small Cell Lung Carcinoma | Details |
| FZ-AD005 | FZ-AD005; FZAD005; F0041 | Phase 1 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Carcinoma, Neuroendocrine; Glioblastoma; Glioma; Small Cell Lung Carcinoma; Solid tumours | Details |
| [89Zr]Zr-BI-764532 | Phase 1 Clinical | Boehringer Ingelheim International Gmbh, C.H. Boehringer Sohn Ag & Co. Kg | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma | Details | |
| ABD-147 | ABD-147; 225Ac-ABD147 | Phase 1 Clinical | Abdera Therapeutics Inc | Neuroendocrine Tumors; Small Cell Lung Carcinoma; Solid tumours | Details |
| SNC-115 | SNC115; SNC-115 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma; Solid tumours | Details |
| RG-6524 | RO-7616789; ALPS-12; RG6524 | Phase 1 Clinical | F. Hoffmann-La Roche Ag | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma | Details |
| OBT620 | OBT620 | Phase 1 Clinical | Boehringer Ingelheim Gmbh, Oxford Biotherapeutics Ltd | Small Cell Lung Carcinoma | Details |
| QLS-31904 | QLS-31904; QLS31904 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| LB-2102(Legend Biotechnology) | LB-2102 | Phase 1 Clinical | Neuroendocrine Tumors; Small Cell Lung Carcinoma | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tarlatamab | AMG-757 | Approved | Amgen Inc | Imdelltra | United States | Small Cell Lung Carcinoma | Amgen Inc | 2024-05-16 | Astrocytoma; Brain metastases; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Ganglioglioma; Glioblastoma; Medullary thyroid cancer (MTC); Melanoma; Neoplasms; Neuroendocrine Tumors; Oligodendroglioma; Paranasal Sinus Diseases; Prostatic Neoplasms; Small Cell Lung Carcinoma; Testicular Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
Product Reviews
n***l2026-04-07
1People LikeThe product worked great and was delivered in a timely manner
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland